Fulcrum Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein from H.C. Wainwright upgraded the rating on the stock to a Buy and gave it a $12.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Fein has given his Buy rating due to a combination of factors that highlight the promising potential of Fulcrum Therapeutics’ drug, pociredir, in treating sickle cell disease (SCD). The recent data from the PIONEER Phase 1b trial demonstrated a significant increase in fetal hemoglobin (HbF) levels, which is crucial as higher HbF levels are associated with fewer vaso-occlusive complications in patients. This increase in HbF, along with improvements in other hematologic parameters, validates pociredir’s ability to mimic the protective effects seen in hereditary persistence of fetal hemoglobin (HPFH).
Moreover, the oral delivery method and favorable safety profile of pociredir make it a scalable and differentiated treatment option, especially when compared to gene editing-based therapies that face logistical challenges. The data also showed a dose-responsive increase in HbF, with a notable number of patients surpassing the clinically significant 20% HbF threshold, which is linked to reduced hospitalizations and crisis rates. These factors collectively support the upgrade to a Buy rating and an increased price target, reflecting the de-risking of the program and the potential for accelerated approval based on HbF as a surrogate endpoint.
Fein covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Biogen, and Palvella Therapeutics. According to TipRanks, Fein has an average return of 9.4% and a 50.40% success rate on recommended stocks.
In another report released today, Oppenheimer also reiterated a Buy rating on the stock with a $15.00 price target.